$30.22
+0.39
(+1.31%)▲
0.89%
Downside
Day's Volatility :1.09%
Upside
0.2%
41.26%
Downside
52 Weeks Volatility :42.2%
Upside
1.6%
Period | Koninklijke Philips N.v | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.9% | 5.1% | 0.0% |
6 Months | 49.25% | 4.9% | 0.0% |
1 Year | 41.68% | 16.6% | 0.0% |
3 Years | -35.27% | 13.2% | -22.3% |
Market Capitalization | 27.9B |
Book Value | $12.72 |
Earnings Per Share (EPS) | -0.65 |
PEG Ratio | 0.35 |
Wall Street Target Price | 27.06 |
Profit Margin | -2.32% |
Operating Margin TTM | 6.23% |
Return On Assets TTM | 1.36% |
Return On Equity TTM | -4.59% |
Revenue TTM | 18.1B |
Revenue Per Share TTM | 19.77 |
Quarterly Revenue Growth YOY | -0.2% |
Gross Profit TTM | 7.2B |
EBITDA | 1.4B |
Diluted Eps TTM | -0.65 |
Quarterly Earnings Growth YOY | 5.85 |
EPS Estimate Current Year | 1.67 |
EPS Estimate Next Year | 1.87 |
EPS Estimate Current Quarter | 0.27 |
EPS Estimate Next Quarter | 0.39 |
What analysts predicted
Downside of 10.46%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 20.6B | ↑ 1.92% |
Net Income | 1.2B | ↓ 34.22% |
Net Profit Margin | 6.02% | ↓ 3.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 21.6B | ↑ 7.51% |
Net Income | 1.3B | ↑ 7.16% |
Net Profit Margin | 6.0% | ↓ 0.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 23.8B | ↑ 0.27% |
Net Income | 1.4B | ↑ 1.63% |
Net Profit Margin | 6.08% | ↑ 0.08% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 19.4B | ↓ 12.18% |
Net Income | 691.8M | ↓ 48.44% |
Net Profit Margin | 3.57% | ↓ 2.51% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 18.9B | ↑ 3.91% |
Net Income | -1.7B | ↓ 364.38% |
Net Profit Margin | -9.08% | ↓ 12.65% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 19.8B | ↑ 1.92% |
Net Income | -508.4M | ↓ 71.2% |
Net Profit Margin | -2.56% | ↑ 6.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.5B | ↓ 23.15% |
Net Income | -709.6M | ↑ 486.73% |
Net Profit Margin | -15.91% | ↓ 13.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 7.27% |
Net Income | 78.1M | ↓ 110.86% |
Net Profit Margin | 1.61% | ↑ 17.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 0.02% |
Net Income | 93.9M | ↑ 22.22% |
Net Profit Margin | 1.97% | ↑ 0.36% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.5B | ↑ 13.22% |
Net Income | 42.5M | ↓ 55.68% |
Net Profit Margin | 0.77% | ↓ 1.2% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.5B | ↓ 18.25% |
Net Income | -1.1B | ↓ 2661.54% |
Net Profit Margin | -24.14% | ↓ 24.91% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↑ 7.83% |
Net Income | 485.3M | ↓ 145.15% |
Net Profit Margin | 10.11% | ↑ 34.25% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 29.6B | ↑ 2.78% |
Total Liabilities | 15.8B | ↑ 4.59% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.0B | ↑ 3.7% |
Total Liabilities | 16.0B | ↑ 3.28% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 33.7B | ↑ 2.71% |
Total Liabilities | 19.2B | ↑ 10.13% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 35.0B | ↑ 11.72% |
Total Liabilities | 18.6B | ↑ 4.27% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 32.5B | ↓ 0.88% |
Total Liabilities | 18.4B | ↑ 5.57% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 32.1B | ↓ 4.18% |
Total Liabilities | 18.9B | ↓ 0.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.8B | ↑ 0.0% |
Total Liabilities | 17.5B | ↓ 6.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.0B | ↓ 3.85% |
Total Liabilities | 18.8B | ↑ 6.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 32.1B | ↓ 0.34% |
Total Liabilities | 18.9B | - |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 31.7B | - |
Total Liabilities | 18.9B | - |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↓ 4.81% |
Investing Cash Flow | -1.7B | ↓ 53.55% |
Financing Cash Flow | -1.4B | ↓ 2267.27% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.3B | ↑ 14.1% |
Investing Cash Flow | -670.1M | ↓ 59.42% |
Financing Cash Flow | -1.9B | ↑ 39.68% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.4B | ↑ 36.73% |
Investing Cash Flow | -1.6B | ↑ 118.24% |
Financing Cash Flow | 587.5M | ↓ 129.01% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 41.34% |
Investing Cash Flow | -4.2B | ↑ 179.03% |
Financing Cash Flow | -2.7B | ↓ 585.92% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -183.1M | ↓ 110.62% |
Investing Cash Flow | -1.6B | ↓ 59.5% |
Financing Cash Flow | 529.1M | ↓ 121.3% |
Q4 FY20 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↑ 284.14% |
Investing Cash Flow | -1.6B | ↑ 131.69% |
Financing Cash Flow | 587.5M | ↓ 35.69% |
Q2 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 914.8M | ↓ 71.74% |
Investing Cash Flow | -3.9B | ↑ 143.69% |
Financing Cash Flow | 242.0M | ↓ 58.39% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 5.7B | ↑ 562.11% |
Investing Cash Flow | -4.2B | ↑ 14.5% |
Financing Cash Flow | -2.7B | ↓ 1267.66% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -625.2M | ↓ 111.74% |
Investing Cash Flow | -927.7M | ↓ 76.12% |
Financing Cash Flow | 369.2M | ↓ 114.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 110.1M | ↓ 117.6% |
Investing Cash Flow | -1.6B | ↑ 69.56% |
Financing Cash Flow | 529.1M | ↑ 43.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 390.5M | ↑ 246.15% |
Investing Cash Flow | -389.4M | ↓ 75.86% |
Financing Cash Flow | -182.2M | ↓ 133.6% |
Sell
Neutral
Buy
Koninklijke Philips N.v is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Koninklijke Philips N.v | 5.15% | 49.25% | 41.68% | -35.27% | -30.87% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Koninklijke Philips N.v | 75.3 | NA | 0.35 | 1.67 | -0.05 | 0.01 | NA | 12.72 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Koninklijke Philips N.v | Hold | $27.9B | -30.87% | 75.3 | -2.32% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Koninklijke Philips N.v
Revenue is up for the last 2 quarters, 4.13B → 4.46B (in $), with an average increase of 7.3% per quarter
Netprofit is up for the last 2 quarters, -999.0M → 451.0M (in $), with an average increase of 321.5% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 9.7%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 116.2%
Mondrian Investment Partners Ltd
Fiduciary Management, Inc. of Milwaukee
FMR Inc
BlackRock Inc
Dimensional Fund Advisors, Inc.
Morgan Stanley - Brokerage Accounts
In the quarter ending September,2022. Koninklijke Philips N.v has declared dividend of $0.91
Read MoreKoninklijke Philips N.V., commonly shortened to Philips, is a Dutch multinational conglomerate corporation that was founded in Eindhoven in 1891. Since 1997, it has been mostly headquartered in Amsterdam, though the Benelux headquarters is still in Eindhoven.
Organization | Koninklijke Philips N.v |
Employees | 68701 |
CEO | Mr. Roy Jakobs |
Industry | Electronic Technology |